Solid tumors with EGFR mutations or amplifications, neratinib monotherapyNeratinib vs. neratinib + temserolimus in NSCLCNeratinib + temserolimus in HER2+ advanced breast cancer*
Solid tumors with EGFR mutations or amplifications, neratinib monotherapy<br>Neratinib vs. neratinib + temserolimus in NSCLC<br>Neratinib + temserolimus in HER2+ advanced breast cancer*
Solid tumors with EGFR mutations or amplifications, neratinib monotherapy<br>Neratinib vs. neratinib + temserolimus in NSCLC<br>Neratinib + temserolimus in HER2+ advanced breast cancer*<br>